| 2022 | AMIA | Deep Representational Clustering for Endotype Discovery. | Amelia J. Averitt, Justin Mower, Nilanjana Banerjee |
| 2021 | AMIA | A Machine Learning Approach to Identify EHR-based Cohorts of Pain Sensitivity for Genetic Analysis. | Amelia J. Averitt, Nilanjana Banerjee, Michael Cantor |
| 2021 | AMIA | A Monte Carlo Estimation of the Narrow-Sense Heritability of COVID-19 Infection and Severity from AncestryDNA Survey Data. | Amelia J. Averitt, Deepika Sharma, Michael Cantor |
| 2020 | AMIA | Adversarially-Learned Balancing Weights for Causal Inference. | Amelia J. Averitt, Natnicha Vanitchanant, Rajesh Ranganath, Adler J. Perotte |
| 2020 | AMIA | The CLinically Explainable Actionable Risk (CLEAR) Model. | Ruijun Chen, Amelia J. Averitt, Oliver J. Bear Don't Walk IV, Shreyas Bhave, Lisa Grossman Liu, Elliot G. Mitchell, Victor Alfonso Rodriguez, Phyllis Thangaraj, Tony Y. Sun |
| 2019 | AMIA | Characterizing the Urban Opioid Epidemic Using EHR Data. | Amelia J. Averitt, Benjamin H. Slovis, Abdul A. Tariq, David K. Vawdrey, Adler J. Perotte |
| 2018 | AMIA | Noisy-Or Risk Allocation Model for Causal Inference. | Amelia J. Averitt, Adler J. Perotte |
| 2017 | AMIA | Clinical Trial Eligibility Criteria Fail to Meet Burden of Generalizability. | Amelia J. Averitt, Chunhua Weng, Adler J. Perotte |
| 2016 | AMIA | Standardization of FDA Adverse Event Reporting System to the OHDSI Common Data Model. | Amelia J. Averitt, Adler J. Perotte |